Abstract
It has been reported that TS-1 can exert antitumor effects on human oral squamous cell carcinoma patients in Japan. However, little is known about the mechanisms of the antitumor activity of TS-1. In this study, we examined the mechanism of the antiangiogenic effects of TS-1 on a human oral squamous cell carcinoma cell line, B88. B88 tumor-bearing nude mice were treated with TS-1 (10 mg/kg/day, 5 days/week), which was administered orally for eight weeks. The TS-1 treatment resulted in a significant suppression of tumor growth, and induced the up-regulation of TSP-1 expression, and the down-regulation of VEGF and CD34 expression immunohistochemically. Overall, these results indicate that TS-1 may inhibit the angiogenecity of human oral cancer cells through the up-regulating TSP-1 expression and the down-regulating VEGF expression.
